Dreams at Risk: Overcoming Barriers for At-Risk Populations
07/22/2010
Challenges of marginalized, HIV positive in Eastern Europe
Life is not that good for injecting drug users in Eastern Europe. Or, for that matter, sex workers, prisoners or anyone else in the high-risk group of marginalized people who have HIV and live on the edge of society there.
A First for Women, New Life for Microbicides
07/20/2010
FHI's Ward Cates on the exciting results of the CAPRISA 004 microbicide trial
The exciting results of the CAPRISA 004 trial released today in Vienna are a hopeful and promising first step towards giving women a new tool to protect themselves from HIV infection. This is the first time that a microbicide trial has shown a significant decrease in the rate of HIV acquisition, with 39 percent fewer infections. Additionally, among women who were the most adherent to the trial regimen, we saw an even greater rate of protection - up to 54 percent. These findings alone are reason for hope, but the trial also presented some other important "firsts."
What Does CAPRISA Mean Future of Microbicides
07/20/2010
Zeda Rosenberg, CEO of the International Partnership for Microbicides, on findings
Today, at the 18th International AIDS Conference in Vienna, the Center for AIDS Programme of Research in South Africa (CAPRISA) announced successful results of a clinical trial testing an antiretroviral (ARV)-based vaginal microbicide for its ability to prevent HIV infection in women. This announcement marks a turning point in efforts to develop safe and effective female-initiated HIV prevention methods. The trial, named CAPRISA 004, showed that women who used a gel containing tenofovir, an ARV commonly used to treat HIV, had a 39 percent lower rate of infection compared to women who used a placebo gel.Haiti Is Everybody’s Business
07/20/2010
GLOBAL HEALTH's Annmarie Christensen on the realities in Haiti
The need to invest in people, develop private-public partnerships, and reduce poverty is what is needed right now in Haiti, participants in a Global Health Council panel told a packed room at the International AIDS Society conference in Vienna June 20.
